Understanding Statins: Benefits, Risks, and Who Should Take Them

How Statins Work

Statins (HMG-CoA reductase inhibitors) block hepatic cholesterol synthesis, upregulate LDL receptors, and lower circulating LDL-C by 30–55% depending on agent and intensity.

Indications (Per ACC/AHA Guidelines)

Statin therapy is recommended for four primary benefit groups:

1. Clinical ASCVD: Prior MI, stroke, PAD, coronary revascularization.
2. Primary LDL-C ≥190 mg/dL: Familial hypercholesterolemia.
3. Diabetes, age 40–75, LDL-C 70–189 mg/dL: Moderate-intensity statin.
4. Age 40–75, LDL-C 70–189 mg/dL, 10-year ASCVD risk ≥7.5%: Moderate-to-high intensity after risk discussion.

Additional risk enhancers (family history, metabolic syndrome, CKD, inflammatory diseases, Lp(a) ≥50 mg/dL, ABI <0.9) support statin initiation in borderline cases.

Common Side Effects

• Muscle symptoms: Myalgia (5–10%), rarely rhabdomyolysis (<0.1%); often dose-related, improved by switching agents or intermittent dosing.
• GI upset: Nausea, constipation, diarrhea – usually transient.
• Metabolic: Small HbA1c increase; new-onset diabetes risk ~0.2%/year, outweighed by CV benefit.
• Hepatic: Asymptomatic transaminase elevation (1–3%); routine monitoring not required unless symptomatic.
• Cognitive: Rare reports of memory issues; not substantiated in trials.

Alternatives for Statin Intolerance

• Ezetimibe (cholesterol absorption inhibitor)
• PCSK9 inhibitors (evolocumab, alirocumab) – injectable, potent LDL lowering
• Bempedoic acid (ATP-citrate lyase inhibitor)
• Bile acid sequestrants, fibrates, niacin – niche roles

Lifestyle Foundation

Mediterranean diet, 150 min/week moderate exercise, weight management, smoking cessation, stress reduction, and alcohol moderation amplify statin benefit and may reduce needed intensity.

Decision-making: Shared clinician-patient discussion using risk calculators (ASCVD Risk Estimator Plus) and patient preferences.